Core Tip: 11 months, around the pharmaceutical industry restructuring, mergers and acquisitions one after another. Shanghai Research Institute of Pharmaceutical Industry, said Xiong Yu,digital thermometer from this year's market situation, the world's major pharmaceutical companies are to achieve universal recovery.
At the same time,clinical thermometer they enter the Chinese market, Chinese pharmaceutical companies began to mergers and acquisitions. This has become China's pharmaceutical market in 2010 one of the biggest features.
Since November, around the pharmaceutical industry restructuring,ear thermometer mergers and acquisitions one after another.
November 1, the French drugmaker Sanofi - Aventis announced that the $ 520,600,000 (about 3.473 billion yuan) acquisition of the pharmaceutical manufacturer and distributor of beauty Huatai Yang Stone Group Corporation. digital blood pressure monitor It is native to China Foreign Pharmaceutical giant OTC (OTC) pharmaceutical companies the largest ever case of a merger.
The same day, the Swiss pharmaceutical company Nycomed to 210 million U.S. dollars to buy private biopharmaceutical company in Guangzhou of China, Temple of the controlling stake. November 3, Sanofi - Aventis announced again, and Hangzhou Minsheng Pharmaceutical Co., Ltd., a joint venture company in Hangzhou Sanofi Minsheng Pharmaceutical Co., Ltd. has been health approved by the Ministry of Commerce.
Shanghai Research Institute of Pharmaceutical Industry, said Xiong Yu, from this year's market situation, the world's major pharmaceutical companies are to achieve universal recovery. At the same time, they enter the Chinese market, Chinese pharmaceutical companies began to mergers and acquisitions. This has become China's pharmaceutical market in 2010 one of the biggest features.
Hot Chinese pharmaceutical market is attracting the attention of all people. "China's pharmaceutical market in the next decade, a compound annual growth rate of 20%, to reach 4.0188 trillion yuan in 2019, becoming the most competitive international markets." State Food and Drug Administration, Southern Medical Economic Institute Lin Jianning think so, which is why foreign giants such rapid layout of the Chinese pharmaceutical market provides a logical background.
The pharmaceutical industry in China, the Secretary-Rui Guozhong technical view, "just open the" golden years "is the pharmaceutical industry to focus on the process of reconstruction and, the result would be to enhance and industry concentration polarization." He told reporter, "Industrial Restructuring and M & A is to focus on the most efficient, most mainstream path, which will open the third round of the Chinese pharmaceutical industry mergers and acquisitions, that is, large M & A era."
Market-oriented products and acquisitions.
Xiong Yu, Shanghai Medical Engineering Institute, told this reporter, in which more than 1 billion yuan-scale mergers and acquisitions, product and market is the most the two major acquisitions. "This year in August, Novartis acquired ACON received approval from the Ministry of Commerce, which represents the future of this piece of anti-infectives in ophthalmology, Novartis share of worldwide sales will account for more than 50% market share in China is expected to more than 60%. "
Unlike in the past year, pharmaceutical mergers and acquisitions, as are overseas pharmaceutical giant to acquire a small pharmaceutical company in China, but the emergence of little-known pharmaceutical company in China acquisition of overseas assets, success stories.
November 9, Hege Lei of China (Dalian) Pharmaceutical Co., Ltd. and Canada URO Technology Co., Ltd. signed the contract, M & A all of its assets and technology, and has become the first medical device company's acquisition of a foreign private enterprise.
Zhe Qin, general manager of the company at the signing ceremony, said the Canadian research and development of digital URO bladder monitoring system in China is still a technical gap, this acquisition will help enhance the digital medical equipment products to developed countries, the mainstream market.
It is reported that the total of China and Canada involved in the acquisition of four companies compete, and ultimately by Hege Lei win.
Shuffling the field of pharmaceutical business increased.
In 2010, China's pharmaceutical industry mergers and acquisitions mainly in the field of medicine distribution.
Rui Guozhong to the Shanghai Securities News pointed out that with the accelerated concentration of pharmaceutical business increased, the future M & A activities between enterprises will be more active. Next 10 years, Chinese medicine business enterprises reduced from the current 12,000 to 2,000.
Now, most have acquired has been hailed as the value of commercial pharmaceutical companies - Nanjing Pharmaceutical, the accumulation of more attention to the eyes.
Public information, holding 100% of the SASAC Nanjing Nanjing Pharmaceutical Industry (Group) Limited ("South pharmaceutical industry"), the latter is 100% owned medicine Nanjing Pharmaceutical Group, the largest shareholder of Southern, South pharmaceutical industry under there are 10 pharmaceutical companies, five commercial pharmaceutical companies, more than 1,000 chain retail pharmacies, in addition to Nanjing Pharmaceutical, also holding a public company - Jinling Pharmaceutical. Back in April, Nanjing Medical or restructuring news to surface.
November 10, Nanjing Medical closed at 15.04 yuan, hit a new high this year. Since the October 28 stock once daily limit has been 10 trading days in the subsequent cumulative increase of nearly 30%. Period, on the Resources, Sinopharm, on drugs, the UK Medical Group AB will participate in bidding for four of Nanjing in the widely circulated news of medicine.
The reporter learned that, "2010-2015 National Development Plan pharmaceutical distribution industry," is expected to put in the year, the program that the "second five" areas of medicine circulation during the focus: to encourage pharmaceutical distribution enterprise mergers and reorganizations, to encourage the retail chain business development, promote national, and municipal leading aircraft carrier Enterprise.